Hepatitis B Virus (HBV) Drug Resistance, Genotype and BCP/Precore Mutations by Sequencing
Also known as: HBVGENOMUT
Use
The test is crucial for detecting mutations in the hepatitis B virus (HBV) that can confer drug resistance and affect treatment strategies. It identifies HBV genotype and mutations in the basal core promoter (BCP) and precore regions which can influence viral behavior and response to antiviral therapy. The interpretation of these mutations aids in personalized treatment planning and management of HBV-infected patients.
Special Instructions
Submit separate specimens when multiple tests are ordered as this test is not performed at ARUP. Prefer Plasma Preparation Tube (PPT) for collection, with alternatives being Lavender (EDTA) or Serum Separator Tube (SST). Ensure patient viral load is over 600 IU/mL.
Limitations
The test is not cleared or approved by the U.S. FDA but is developed and its performance characteristics determined by Quest Diagnostics pursuant to CLIA regulations. It may lack detection of certain mutations or resistance profiles not yet established, such as for tenofovir. Test performance is contingent on adherence to specimen requirements.
New York Approved
Methodology
PCR-based
Biomarkers
LOINC Codes
- 16934-2
- 32366-7
- 33633-9
- 54210-0
- 32366-7
- 16934-2
- 33633-9
- 54210-0
Result Turnaround Time
9-13 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect using a Plasma Preparation Tube (PPT), Lavender (EDTA), or Serum Separator Tube (SST). Separate from cells ASAP or within 2 hours of collection.
Storage Instructions
Frozen.
Causes for Rejection
Thawed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |
Other tests from different labs that may be relevant